Is Prolonged Daratumumab Maintenance Useful in Light-Chain Amyloidosis?
Daratumumab-based therapy is a cornerstone of treatment for light-chain (AL) amyloidosis; however, the optimal treatment duration remains undefined. We retrospectively analyzed 399 newly diagnosed AL amyloidosis patients treated at 2 centers according to center-specific planned daratumumab treatment durations (12 vs ≥ 24 cycles). Overall survival (OS), cumulative incidence of next treatment, and organ responses were compared using an intention-to-treat approach. A separate cohort of 184 relapsed/refractory patients was similarly analyzed. The 12- and ≥ 24-cycle cohorts included 181 and 218 patients, respectively. OS and cumulative incidence of next treatment were comparable between groups (P = 0.639 and P = 0.336, respectively), including among patients aged ≥ 65 years and those with bone marrow plasma cell ≥ 10%. Extended treatment increased the 24-month rate of renal responses ≥very good partial response (42% vs 26%; P = 0.023) but did not improve cardiac responses. Similar findings were observed in relapsed/refractory patients, with better renal responses but no OS or next-treatment benefit. Overall, treatment beyond 12 cycles was not associated with statistically significant improvements in OS or a lower cumulative incidence of next treatment, although clinically meaningful effects cannot be excluded. Prospective studies are needed to clarify the potential benefits of prolonged daratumumab treatment in AL amyloidosis.
Authors
- Mario Nuvolone (ORCID: https://orcid.org/0000-0001-8334-1684)
- Marco Basset (ORCID: https://orcid.org/0000-0003-3829-0499)
- Shen Kai-ni
- Claudia Bellofiore (ORCID: https://orcid.org/0000-0002-4388-1835)
- Giovanni O. Palladini (ORCID: https://orcid.org/0000-0001-5994-5138)
- Paolo Milani (ORCID: https://orcid.org/0000-0002-2268-9422)
- Jian Li (ORCID: https://orcid.org/0000-0002-4549-0694)
- Chengyang Xu (ORCID: https://orcid.org/0000-0003-0076-8282)
- Ai Guan (ORCID: https://orcid.org/0000-0002-6946-6488)
- Yi Xu
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Pavia (IT)
- Peking Union Medical College Hospital (CN)
- Policlinico San Matteo Fondazione (IT)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11583799/v1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- preprint
Funders
- European Commission
- National Natural Science Foundation of China
- Fondazione Cariplo
- Peking Union Medical College Hospital
- NextGenerationEU